CJC-1295 research guide for Aknalich. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers trying to source CJC-1295 in Aknalich soon discover that local retail options are essentially nonexistent. This matters because CJC-1295 quality ranges widely across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor is the entire quality system. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. The sections below cover what Aknalich researchers need to know about purchasing, testing, and working with CJC-1295 for legitimate research applications.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Aknalich researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, establish a quality benchmark — so you can tell whether a COA is complete and credible. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. The combination of peer feedback and direct document verification is the gold standard for CJC-1295 sourcing — community feedback surfaces systemic problems invisible in one transaction, and vice versa. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Aknalich
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by aliquoting into single-use portions. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that rigorous vendor evaluation eliminates. PubMed are the primary literature resources for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over conference abstracts or single case observations.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
